Eli Lilly beats Q3 estimates, revenue up 38.6% to $24.4 billion
The gist
Eli Lilly reported Q3 2026 revenue of $24.4 billion, beating the $22.61 billion consensus.
Obesity and diabetes drug sales are driving record highs and a $1.17 trillion valuation.
How it unfolded
- Oct 19, 2026Lilly announced Omvoh delivered positive one-year Phase 3 results in patients ages 6 to 17 with moderately to severely active ulcerative colitis.
- Oct 20, 2026Lilly shares hit an all-time high of $1,311.75.
- Oct 23, 2026Shares reached a new 52-week high of $1,321.21.